BMS-986365 is a new medicine being tested to see if it can help treat metastatic castration-resistant prostate cancer, a type of cancer that has spread and does not respond to treatments that lower testosterone. The goal of using BMS-986365 in this study is to find out if it can slow down the progression of the disease better than other treatments chosen by doctors.

Docetaxel is a type of chemotherapy used to treat various cancers, including prostate cancer. It works by stopping cancer cells from growing and dividing, which can help slow down or stop the spread of the disease. In this study, Docetaxel is one of the treatment options that doctors might choose to compare against the new medicine, BMS-986365.

Second Androgen Receptor Pathway Inhibitor (ARPI) is a type of treatment that targets the androgen receptors in prostate cancer cells. These receptors help the cancer grow, and by blocking them, the treatment can slow down the cancer’s progression. In this study, a second ARPI is another treatment option that doctors might choose to compare against the new medicine, BMS-986365.

Metastatic Castration-resistant Prostate Cancer – This disease is a form of prostate cancer that continues to progress despite treatments that lower testosterone, which typically fuels prostate cancer growth. It is characterized by the spread of cancer cells beyond the prostate gland to other parts of the body, such as bones or lymph nodes. The cancer cells in this condition are resistant to hormonal therapy aimed at reducing male hormones. As the disease advances, patients may experience symptoms related to the spread of cancer, such as bone pain or urinary issues. The progression of the disease is often monitored through imaging techniques to assess the spread and growth of cancerous cells. The condition is a significant challenge in prostate cancer management due to its resistance to conventional hormone therapies.